TNFSF14 and neoplasm: Targeting LIGHT/TNFSF14 to tumor vessels through fusion to a vascular-targeting peptide (LIGHT-VTP) prolonged survival and sensitized RIP1-Tag5 pancreatic tumors to immunotherapies, while inducing formation of TLS and PNAd+ TA-HEVs (26).